|
Market Closed -
Other stock markets
|
Pre-market 12:39:37 | |||
| 25.62 USD | -1.61% |
|
25.70 | +0.33% |
| 11:57am | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 06-08 | AstraZeneca's Obesity Pill Helps Patients Lose Weight in Midstage Trials | DJ |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 81.29B | 100B | 58.5B | 63.63B | 62.58B | |||||
Total Revenues | 81.29B | 100B | 58.5B | 63.63B | 62.58B | |||||
Cost of Goods Sold, Total | 30.66B | 34.1B | 23.99B | 17.19B | 15.14B | |||||
Gross Profit | 50.63B | 66.23B | 34.51B | 46.44B | 47.44B | |||||
Selling General & Admin Expenses, Total | 9.56B | 12.2B | 13.84B | 14.77B | 12.96B | |||||
R&D Expenses | 10.52B | 11.43B | 10.68B | 10.74B | 10.44B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 3.7B | 3.61B | 4.73B | 5.29B | 4.87B | |||||
Other Operating Expenses, Total | 23.78B | 27.24B | 29.25B | 30.8B | 28.28B | |||||
Operating Income | 26.84B | 39B | 5.26B | 15.64B | 19.16B | |||||
Interest Expense, Total | -1.29B | -1.24B | -2.21B | -3.09B | -2.67B | |||||
Interest And Investment Income | 202M | 565M | 2.1B | 817M | 868M | |||||
Net Interest Expenses | -1.09B | -673M | -109M | -2.27B | -1.8B | |||||
Income (Loss) On Equity Invest. | 471M | 436M | 505M | 102M | - | |||||
Currency Exchange Gains (Loss) | -192M | -1.15B | 164M | 50M | - | |||||
Other Non Operating Income (Expenses) | 1.88B | 2.62B | 1.28B | 652M | 1.55B | |||||
EBT, Excl. Unusual Items | 27.92B | 40.22B | 7.09B | 14.17B | 18.91B | |||||
Restructuring Charges | -1.36B | -2.02B | -3.33B | -2.73B | -1.85B | |||||
Merger & Related Restructuring Charges | - | -200M | -668M | -1.4B | -773M | |||||
Gain (Loss) On Sale Of Investments | 1.34B | -1.27B | 1.59B | 1.83B | -134M | |||||
Gain (Loss) On Sale Of Assets | 99M | - | 222M | -420M | - | |||||
Asset Writedown | -86M | -421M | -3.02B | -3.3B | -4.94B | |||||
In Process R&D Expenses | - | -953M | -194M | -108M | -1.61B | |||||
Insurance Settlements | - | - | - | - | - | |||||
Legal Settlements | -182M | -230M | -474M | -567M | -1.06B | |||||
Other Unusual Items | -3.42B | -394M | -157M | 532M | -1.02B | |||||
EBT, Incl. Unusual Items | 24.31B | 34.73B | 1.06B | 8.02B | 7.52B | |||||
Income Tax Expense | 1.85B | 3.33B | -1.12B | -28M | -266M | |||||
Earnings From Continuing Operations | 22.46B | 31.4B | 2.17B | 8.05B | 7.79B | |||||
Earnings Of Discontinued Operations | -434M | 6M | -15M | 11M | 25M | |||||
Net Income to Company | 22.02B | 31.41B | 2.16B | 8.06B | 7.81B | |||||
Minority Interest | -45M | -35M | -39M | -31M | -41M | |||||
Net Income - (IS) | 21.98B | 31.37B | 2.12B | 8.03B | 7.77B | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 21.98B | 31.37B | 2.12B | 8.03B | 7.77B | |||||
Net Income to Common Excl. Extra Items | 22.41B | 31.37B | 2.13B | 8.02B | 7.75B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 3.92 | 5.59 | 0.38 | 1.42 | 1.37 | |||||
Basic EPS - Continuing Operations | 4 | 5.59 | 0.38 | 1.42 | 1.36 | |||||
Basic Weighted Average Shares Outstanding | 5.6B | 5.61B | 5.64B | 5.66B | 5.68B | |||||
Net EPS - Diluted | 3.85 | 5.47 | 0.37 | 1.41 | 1.36 | |||||
Diluted EPS - Continuing Operations | 3.93 | 5.47 | 0.37 | 1.41 | 1.36 | |||||
Diluted Weighted Average Shares Outstanding | 5.71B | 5.73B | 5.71B | 5.7B | 5.71B | |||||
Normalized Basic EPS | 3.11 | 4.48 | 0.78 | 1.56 | 2.07 | |||||
Normalized Diluted EPS | 3.05 | 4.38 | 0.77 | 1.55 | 2.06 | |||||
Dividend Per Share | 1.56 | 1.6 | 1.64 | 1.68 | 1.72 | |||||
Payout Ratio | 39.72 | 28.63 | 436.38 | 118.44 | 125.74 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 31.95B | 44.02B | 11.52B | 22.64B | 25.72B | |||||
EBITA | 30.54B | 42.6B | 9.99B | 20.93B | 24.04B | |||||
EBIT | 26.84B | 39B | 5.26B | 15.64B | 19.16B | |||||
EBITDAR | 32.84B | 45.24B | 12.8B | 23.81B | 26.64B | |||||
Total Revenues (As Reported) | - | - | 58.5B | 63.63B | 62.58B | |||||
Effective Tax Rate - (Ratio) | 7.62 | 9.58 | -105.39 | -0.35 | -3.54 | |||||
Current Domestic Taxes | 3.38B | 2.72B | 1.19B | 485M | 556M | |||||
Current Foreign Taxes | 2.77B | 4.37B | 1.14B | 1.59B | 1.31B | |||||
Total Current Taxes | 6.14B | 7.09B | 2.33B | 2.07B | 1.87B | |||||
Deferred Domestic Taxes | -4.34B | -3.58B | -2.79B | -2.2B | -1.89B | |||||
Deferred Foreign Taxes | 48M | -183M | -652M | 100M | -246M | |||||
Total Deferred Taxes | -4.29B | -3.76B | -3.44B | -2.1B | -2.13B | |||||
Normalized Net Income | 17.4B | 25.11B | 4.39B | 8.83B | 11.78B | |||||
Interest Capitalized | 108M | 124M | 160M | 182M | 166M | |||||
Non-Cash Pension Expense | -2.14B | -247M | -508M | 150M | -506M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2B | 2.8B | 3.7B | 3.3B | 2.7B | |||||
Selling and Marketing Expenses | 2B | 2.8B | 3.7B | 3.3B | 2.7B | |||||
Research And Development Expense From Footnotes | 13.83B | 11.43B | 10.87B | 10.93B | 12.05B | |||||
Net Rental Expense, Total | 888M | 1.22B | 1.28B | 1.18B | 924M | |||||
Imputed Operating Lease Interest Expense | 240M | 329M | 424M | 432M | 311M | |||||
Imputed Operating Lease Depreciation | 648M | 889M | 859M | 745M | 613M | |||||
Stock-Based Comp., Other (Total) | 1.2B | 891M | 545M | 893M | 799M | |||||
Total Stock-Based Compensation | 1.2B | 891M | 545M | 893M | 799M |
- Stock Market
- Stocks
- PFE Stock
- Financials Pfizer Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















